The Acute Coronary Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Acute Coronary Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acute Coronary Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acute Coronary Syndrome and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for Acute Coronary Syndrome by 16 companies/universities/institutes. The top development phase for Acute Coronary Syndrome is phase i with five drugs in that stage. The Acute Coronary Syndrome pipeline has 16 drugs in development by companies and one by universities/ institutes. Some of the companies in the Acute Coronary Syndrome pipeline products market are: Hyloris Pharmaceuticals, Shaanxi Micot Technology and Beijing SH biotechnology.
The key targets in the Acute Coronary Syndrome pipeline products market include P2Y Purinoceptor 12, Prothrombin, and Proprotein Convertase Subtilisin/Kexin Type 9.
The key mechanisms of action in the Acute Coronary Syndrome pipeline product include P2Y Purinoceptor 12 Antagonist with five drugs in Pre-Registration. The Acute Coronary Syndrome pipeline products include five routes of administration with the top ROA being Oral and five key molecule types in the Acute Coronary Syndrome pipeline products market including Small Molecule, and Synthetic Peptide.
Acute Coronary Syndrome overview
Acute coronary syndrome (ACS) encompasses ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina, constituting a subset of coronary heart disease (CHD) responsible for a third of deaths in individuals over 35. Unlike some asymptomatic forms of CHD, ACS is always symptomatic. Diagnosis begins with an ECG, crucial for distinguishing between STEMI, NSTEMI, and unstable angina. Initial ACS treatment involves aspirin (300 mg), heparin bolus, and intravenous (IV) heparin infusion, barring contraindications. Antiplatelet therapy with ticagrelor or clopidogrel is also advised, forming essential components of the comprehensive ACS management protocol.
For a complete picture of Acute Coronary Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
